Clinical Trials Directory

Trials / Completed

CompletedNCT05795556

Biomarkers of Sarcopenia and Frailty in Geriatric Patients

Status
Completed
Phase
Study type
Observational
Enrollment
508 (actual)
Sponsor
Herlev and Gentofte Hospital · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

During the last decades there has been an increase in the relative proportion and life expectancy of elderly people. Hence, the number of elderly with diseases and disabilities related to aging will increase and consequently, age-related losses in skeletal muscle mass and physical function represents an important current and future public health issue. Sarcopenia is a progressive and generalized skeletal muscle disorder that is considered central to the development of physical deconditioning and untreated sarcopenia is linked to falls, morbidity, and mortality. The underlying mechanisms behind the progressive loss of muscle mass and function associated with aging are yet unknown but seems to be multifactorial. A decrease in physical activity level and an altered central and peripheral nervous system innervation have been identified as some of the contributing factors. Furthermore, chronic low-grade inflammation has been proposed as a central contributor to sarcopenia and thus physical frailty. However, it is not yet clear whether the elevated markers of inflammation seen in the elderly are due to aging, chronic illness, or inactivity. But overall, it seems that inflammation plays an important role in the development of muscle loss, and is related to increased risk of falls, fragility, and early death.

Conditions

Interventions

TypeNameDescription
OTHERAssessing sarcopenia and potential biomarkers of sarcopenia in fall patientsBlood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)

Timeline

Start date
2021-11-08
Primary completion
2023-10-31
Completion
2024-06-30
First posted
2023-04-03
Last updated
2025-03-12

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05795556. Inclusion in this directory is not an endorsement.